Unceded territories of the xʷməθkʷəy̓əm (Musqueam), Sḵwx̱wú7mesh (Squamish) and səlilwətaɬ (Tsleil-Waututh) First Nations (Vancouver, B.C., Canada) – Today, the Canadian Drug Policy Coalition (CDPC) released the findings…
Expanded Response Options to Opioid Harms: Case Study from Four Cities
COVID-19 pandemic compounds an ongoing public health crisis. There is a heightened need to reduce avoidable pressures on healthcare systems and support people who use opioids.
‘Safer opioid distribution’ as an essential public health intervention for opioid mortality crisis
Given the persistent opioid mortality crisis especially in North America, the time has come to move towards providing risk population-wide SOD as an essential public health intervention
Expanding access to diacetylmorphine & hydromorphone in Canada
Click HERE for more resources Abstract: The increasing incidence of fatal opioid overdose is a public health crisis in Canada. While buprenorphine/naloxone and methadone are the standard…
COVID-19: Information for OAT Prescribers and Pharmacists
Many patients on OAT currently receive daily witnessed medications. In the context of the COVID-19 pandemic, there may be additional considerations for access that prescribers and pharmacists should be aware of.
Prescriber Guidelines Risk Mitigation in Dual Public Health Emergencies
VCH has new guidelines in place to help prescribers support people who use drugs (PWUD) who need assistance managing withdrawal symptoms due to COVID-19.
FAQ: Class Exemption for Controlled Substances during COVID-19
In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.
CDSA Exemption and Interpretive Guide for Controlled Substances
“We strongly encourage all partners to work to implement these exemptions in their jurisdictions
and welcome any additional suggestions you may have to maintain Canadians’ access to
controlled substances for medical reasons during the pandemic.”
COVID-19 Guidance for Clinicians & Opioid Treatment Programs
Guidance from the Yale Program in Addiction Medicine
